Pharmaceutical composition for treating papillomavirus tumors and infection
AssigneeTransgene S.A.
InventorsJean-Marc Balloul, Nadine Bizouarne, Marie-Paule Kieny
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition for treating or preventing a papillomavirus infection or tumour, including, as the therapeutical agents, a polypeptide from an early region and a polypeptide from a late region of a papillomavirus, optionally combined with a polypeptide having immunostimulatory activity or a polypeptide from an early or late region of a papillomavirus and a polypeptide having immunostimulatory activity, or alternatively, a recombinant vector containing inserted DNA fragments coding for the above-mentioned polypeptide combinations.
Claims15
A composition consisting of a recombinant modified Ankara (MVA) vector into which is inserted within excisions II and/or III DNA sequences coding for (i) the early E6 polypeptide of a papillomavirus;
- (ii) the early E7 polypeptide of a papillomavirus;
- (iii) the late L1 polypeptide of a papillomavirus;
- and (iv) the late L2 polypeptide of a papillomavirus;
- and (v) a polypeptide having an immunostimulatory activity;
- wherein each of said DNA sequences is placed under the control of the independent elements necessary for its expression in a host cell or organism and wherein said polypeptide having an immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, and the co-adhesion molecule B7.2;
- and
- wherein said recombinant MVA vector is provided in combination with a pharmaceutically acceptable carrier.
A composition consisting of a recombinant modified Ankara (MVA) vector into which is inserted within excision II or III DNA sequences coding for (i) the E6 polypeptide of a papillomavirus (ii) the E7 polypeptide of a papillomavirus and (iii) a polypeptide having an immunostimulatory activity;
- each of said DNA sequences being placed under the control of independent elements necessary for its expression in a host cell or organism and wherein said polypeptide having an immunostimulatory activity is selected from the group consisting of interleukin-2, interleukin-7, and the co-adhesion molecule B7.2;
- and
- wherein said recombinant MVA vector is provided in combination with a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.